npj Precision Oncology

Article	Citations
Machine learning approaches to drug response prediction: challenges and recent progress	158
3D bioprinting for reconstituting the cancer microenvironment	153
Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning	113
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients	107
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer	76
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population	73
High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients	62
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma	54
Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients	50
Microbiome dysbiosis in lung cancer: from composition to therapy	50
Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty	48
Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics	48
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy	45
Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity	45
GD2 CAR T cells against human glioblastoma	42
ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma	38
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response	37
Multiplexed drug testing of tumor slices using a microfluidic platform	35
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance	34
Will polygenic risk scores for cancer ever be clinically useful?	34
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes	32
Clinical application of a lung cancer organoid (tumoroid) culture system	31
Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning	31
PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer	31
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition	31

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib	30
High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition	28
Dynamic roles of inflammasomes in inflammatory tumor microenvironment	28
Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets	28
A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients	27
Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology	26
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors	26
Deep learning for end-to-end kidney cancer diagnosis on multi-phase abdominal computed tomography	26
Identification of gastric cancer subtypes based on pathway clustering	25
Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes	25
Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer	24
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy	24
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients	23
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer	23
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient	22
Survival improvement for patients with metastatic colorectal cancer over twenty years	21
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)	21
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA	21
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis	21
Antibody-drug conjugates in lung cancer: dawn of a new era?	20
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome	20
Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma	20
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer	20
Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor	19
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer	19
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC	19
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer	19
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance	19
Cell graph neural networks enable the precise prediction of patient survival in gastric cancer	19
Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer	18
Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma	18
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia	18
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells	18
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas	18
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy	18
Just Add Data: automated predictive modeling for knowledge discovery and feature selection	18
Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma	18
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets	18
Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury	17
Prostate cancer polygenic risk score and prediction of lethal prostate cancer	17
Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review	17
Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images	17
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis	17
Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies	17
Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features	17
The identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma	17
Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer	17
Self-supervised attention-based deep learning for pan-cancer mutation prediction from histopathology	17
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors	16
Targeting CDK1 in cancer: mechanisms and implications	16

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures	16
Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns	16
Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment	16
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial	16
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade	16
Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups	16
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade	16
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy	16
Accurate surgical navigation with real-time tumor tracking in cancer surgery	16
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors	16
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics	16
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma	15
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer	15
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma	15
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition	15
Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions	15
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial	15
Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity	15
The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia	15
A deep learning model for molecular label transfer that enables cancer cell identification from histopathology images	15
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients	15
Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma	15
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer	15
Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1	14
Usability of deep learning and H&E images predict disease outcome-emerging tool to optimize clinical trials	14
Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma	14
Rare deleterious germline variants and risk of lung cancer	14
Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium	14
Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance	13
Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types	13
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?	13
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer	12
Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes	12
Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study	12
Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations	12
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features	12
Imaging immunity in patients with cancer using positron emission tomography	12
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target	12
Spatially variant immune infiltration scoring in human cancer tissues	12
Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma	12
Artificial intelligence for the next generation of precision oncology	12
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study	11
A DNA methylation-based liquid biopsy for triple-negative breast cancer	11
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies	11
Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells	11
Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy	11
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis	10
Prediction of early-stage melanoma recurrence using clinical and histopathologic features	10
Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality	10
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	10
DNA-based copy number analysis confirms genomic evolution of PDX models	10
Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia	10
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer	10
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations	10
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity	10
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia	10
Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation	10
Annotation and cluster analysis of long noncoding RNA linked to male sex and estrogen in cancers	10
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance	10
Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification	10
Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors	10
Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer	10
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy	10
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma	9
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer	9
Impact of TP53 mutations in Triple Negative Breast Cancer	9
Swiss-PO: a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology	9
Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case	9
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression	9
Gas6 expression is reduced in advanced breast cancers	9
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	9
Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy	9
Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors	9
Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis	9
Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review	9
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer	9
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer	9
Patient-level proteomic network prediction by explainable artificial intelligence	9
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer	9
Genomic landscape of 891 RET fusions detected across diverse solid tumor types	9

Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases	9
Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients	9
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations	9
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients	9
Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer	8
Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma	8
Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma	8
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression	8
Racial and ethnic disparities in a real-world precision oncology data registry	8
A patient-designed tissue-engineered model of the infiltrative glioblastoma microenvironment	8
Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication	8
STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis	8
Epigenomics and immunotherapeutic advances in pediatric brain tumors	8
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)	8
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM	8
Precision medicine: affording the successes of science	8
Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma	7
Panels and models for accurate prediction of tumor mutation burden in tumor samples	7
Advances in NK cell therapy for brain tumors	7
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study	7
Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy	7
Deep learning generates synthetic cancer histology for explainability and education	7
A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival	7
Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers	7
BAP1 methylation: a prognostic marker of uveal melanoma metastasis	7
Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers	7
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements	7
MatchMiner: an open-source platform for cancer precision medicine	7
FOXP3+ T cells in uterine sarcomas are associated with favorable prognosis, low extracellular matrix expression and reduced YAP activation	7
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer	7
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology	6
Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway	6
Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction	6
Multi-site desmoplastic small round cell tumors are genetically related and immune-cold	6
Comprehensive molecular profiling of pulmonary pleomorphic carcinoma	6
Clinical implications of systemic and local immune responses in human angiosarcoma	6
PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN	6
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity	6
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib	6
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration	6
Radiomics for characterization of the glioma immune microenvironment	5
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer	5
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing	5
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system	5
Artificial intelligence in ovarian cancer histopathology: a systematic review	5
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival	5
Polygenic risk scores to stratify cancer screening should predict mortality not incidence	5
Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment	5
SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas	5
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas	5
Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy	5
Tumor-associated macrophage-related strategies for glioma immunotherapy	5
Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer	5
Hypermutated phenotype in gliosarcoma of the spinal cord	5
Clinical prospects of WRN inhibition as a treatment for MSI tumours	5
Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC	5